Search clinical trials for: Empagliflozin 10 mg Tab

Total 1765 results

Amsterdam UMC, location VUmc

Completed

Renohemodynamic Effects of Combined empagliflOzin and LosARtan (RECOLAR)

Diabetes Mellitus, Type 2 | Diabetic Kidney Disease

Netherlands
Juntendo University
Boehringer Ingelheim

Recruiting

Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure (EMPA-AHF)

Acute Heart Failure

Japan
Jacob Moller
Rigshospitalet, Denmark; University Hospital Bispebjerg and Frederiksberg; Hillerod... and other collaborators

Recruiting

The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart Failure

Heart Failure | Obesity

Denmark
Mario Negri Institute for Pharmacological Research
Boehringer Ingelheim

Withdrawn

SGLT2 Inhibitors in Glomerular Hyperfiltration (EMPATHY)

Obesity | Non-diabetic Chronic Kidney Disease
Ann & Robert H Lurie Children's Hospital of Chicago
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Not yet recruiting

Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease (SGLT2I-IN-KIDS)

Chronic Kidney Diseases | Pediatric Kidney Disease

United States
Hannover Medical School
Boehringer Ingelheim

Not yet recruiting

Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD) (EMPA-PKD)

Autosomal Dominant Polycystic Kidney
Chulalongkorn University

Not yet recruiting

The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1 (TREAT-CRS)

Empagliflozin in Cardiorenal Syndrome Type 1

Thailand
Chinese University of Hong Kong

Recruiting

Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction (EMPA)

Acute Heart Failure

Hong Kong
Chulalongkorn University

Recruiting

The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors

Empagliflozin in Post AKI Stage 2-3

Thailand
Jacob Moller
Rigshospitalet, Denmark; University Hospital Bispebjerg and Frederiksberg; Hillerod... and other collaborators

Recruiting

The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure

Heart Failure | Obesity

Denmark
Assiut University

Completed

Effect of Sodium Glucose Cotransporter Inhibitors on Non Diabetic Fatty Liver Disease Patients (Fatty liver)

Fatty Liver Disease

Egypt
Morten Schou

Completed

Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction (Empire HF)

Heart Failure With Reduced Ejection Fraction

Denmark
Medical University of Vienna

Completed

Empagliflozin in Post-Transplantation Diabetes Mellitus (EMPTRA-DM)

Posttransplant Diabetes Mellitus

Austria
Ain Shams University

Not yet recruiting

Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin

Cancer
Alexandria University

Recruiting

Effect of Empagliflozin on NT-Pro Brain Natriuretic Peptide in Heart Failure Patients With Reduced Ejection Fraction

Heart Failure With Reduced Ejection Fraction

Egypt
Maria Sklodowska-Curie National Research Institute...
Medical Research Agency, Poland

Recruiting

Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines (EMPACT)

Cardiotoxicity

Poland
National Institute of Cardiology, Warsaw, Poland
Amsterdam UMC, location VUmc; University of Eastern Finland; Medical University...

Recruiting

Empagliflozin in Hypertrophic Cardiomyopathy (EMPA-REPAIR)

Heart Failure | Hypertrophic Cardiomyopathy

Poland
NHS Greater Glasgow and Clyde
University of Glasgow

Active, not recruiting

EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction (EMPRESS-MI)

Myocardial Infarction

United Kingdom
Centre Hospitalier Universitaire Vaudois

Completed

Empagliflozin and Renal Oxygenation in Healthy Volunteers (EMPA-REIN)

Nephropathy

Switzerland
Seoul National University Bundang Hospital

Recruiting

Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety (Location-F)

Diabetes Type 2

Korea, Republic of
NYU Langone Health
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Boehringer...

Recruiting

Safety and Efficacy of Empagliflozin in Hemodialysis (SEED)

End Stage Renal Disease

United States
China National Center for Cardiovascular Diseases

Recruiting

Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension

Hypertension | Pre-Heart Failure

China
Yale University
Boehringer Ingelheim

Recruiting

Empagliflozin in Patients With Cirrhosis and Ascites (EMPA Liver)

Liver Failure | Cirrhosis

United States
University Medical Center Groningen

Completed

Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure (EMPA-RESPONSE)

Heart Failure; With Decompensation | Heart Failure，Congestive | Heart Failure Acute

Netherlands
Singapore General Hospital
Duke-NUS Graduate Medical School

Terminated

Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN) ((MEDiaN))

Diabetic Nephropathies

Singapore
NHS Greater Glasgow and Clyde
University of Glasgow

Completed

Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects (SUGAR-DM-HF)

Heart Failure | Diabetes Mellitus

United Kingdom
Pharma Nueva

Not yet recruiting

A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting Conditions

Healthy Vollunteer
Medical University of Vienna
Attoquant Diagnostics

Completed

EMPRA (EMPagliflozin and RAs in Kidney Disease) (EMPRA)

Diabetes Mellitus, Type 2 | Diabetic Kidney Disease | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3

Austria
AstraZeneca

Completed

The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions

Healthy Subjects in Fasted and Fed State

Brazil
Alexandria University

Completed

Empagliflozin as a Novel Therapy in Refractory Ascites

Ascites Hepatic

Egypt
Benha University
Hawaa Fertility Center

Suspended

Montelukast for Prevention & Treatment of OHSS

Ovarian Hyperstimulation Syndrome

Egypt
SINA Health Education and Welfare Trust

Completed

Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity

Polycystic Ovary Syndrome | Weight Gain | HbA1c

Pakistan
Bayer

Recruiting

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes (CONFIDENCE)

Type 2 Diabetes Mellitus | Chronic Kidney Disease

United States, Belgium, Spain, Taiwan, Korea, Republic of, Japan, Italy, Denmark, Israel, Canada, France, India, Netherlands, Germany
Maastricht University
AstraZeneca

Completed

Effects of 2 Weeks Treatment With Dapagliflozin in Subjects With an Impaired Glucose Homeostasis on Nocturnal Substrate Oxidation (MaasFlex)

Prediabetic State | Substrate Oxidation

Netherlands
Janssen Scientific Affairs, LLC

Completed

A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care

HIV-1

United States
Spanish Society of Cardiology
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III

Active, not recruiting

Dapagliflozin After Transcatheter Aortic Valve Implantation (DapaTAVI)

Aortic Stenosis | Transcatether Aortic Valve Implantation

Spain
Mount Sinai Hospital, Canada
Boehringer Ingelheim

Recruiting

Empagliflozin and the Preservation of Beta-cell Function in Women With Recent Gestational Diabetes (EMPA post-GDM)

Gestational Diabetes

Canada
General and Teaching Hospital Celje

Completed

Novel Therapeutics and Endothelial Dysfunction in T1DM Patients (ENDIS)

Diabetes Mellitus, Type 1 | Biomarkers | Endothelial Dysfunction | Arterial Stiffness | FMD | Incretins | Endothelial Progenitor Cells | SGLT 2 Inhibitors | Glucose Excursions | FPF

Slovenia
Cairo University

Active, not recruiting

Efficacy and Safety of Dapagliflozin in Patients With Non-alcoholic Steatohepatitis

Non-alcoholic Steatohepatitis

Egypt
Miulli General Hospital

Not yet recruiting

Empagliflozin and Atrial Fibrillation Treatment (EMPA-AF)

Heart Failure | Obesity | Diabetes Mellitus | Atrial Fibrillation

Italy
Holbaek Sygehus

Enrolling by invitation

Reduction of Peritoneal Glucose Uptake With Use of SGLT2 in Humans Undergoing Peritoneal Dialysis Treatment (PRESERVE)

End Stage Renal Disease | Peritoneal Dialysis Complication

Denmark
George Clinical Pty Ltd
University Medical Center Groningen; Ground Zero Pharmaceuticals

Unknown

An Open Label Phase IV Study to Evaluate Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Impaired Renal Function

Diabetes Mellitus, Type 2 | Impaired Renal Function

Canada
Chong Kun Dang Pharmaceutical

Completed

Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of CKD-333 in Healthy Volunteers

Hypertension | Dyslipidemias

Korea, Republic of
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets

Healthy

Germany
Medical University of Graz
Medical University of Vienna; Johannes Kepler University of Linz; Paracelsus... and other collaborators

Completed

Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction (EMMY)

Acute Myocardial Infarction

Austria
AstraZeneca

Completed

A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes (DERIVE)

Type 2 Diabetes Mellitus

United States, Italy, Spain, Sweden, Canada, Bulgaria, Poland, Czechia
Jinnah Postgraduate Medical Centre

Not yet recruiting

Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD

Non-Alcoholic Fatty Liver Disease | Type2diabetes

Pakistan
University of Campinas, Brazil
AstraZeneca

Completed

Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery (ADDENDA)

Coronary Artery Disease | Diabetes Mellitus, Type 2 | Carotid Artery Diseases

Brazil
Dong-A University

Recruiting

Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients

Renal Insufficiency, Chronic | Percutaneous Coronary Intervention | Cardiac Catheterization

Korea, Republic of
Northwestern University
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Recruiting

Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

Heart Failure | Kidney Diseases | Chronic Kidney Diseases | Heart Failure With Preserved Ejection Fraction

United States

Search clinical trials for: Empagliflozin 10 mg Tab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations